NEW YORK (GenomeWeb) – Rheonix will soon begin a clinical trial for a microarray-based test for sexually transmitted infections with the aim of submitting the assay to the US Food and Drug Administration for clearance next year.

President Tony Eisenhut said that the Ithaca, NY-based molecular diagnostics company has used the $14 million it raised last year to finish the development of its EncompassMDx platform and Rheonix CARD cartridges and is now ready to continue on its path to the clinical market with its debut test, dubbed STI Tri-Plex.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.